Andrea Maes

882 total citations
32 papers, 685 citations indexed

About

Andrea Maes is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Pharmacology. According to data from OpenAlex, Andrea Maes has authored 32 papers receiving a total of 685 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 13 papers in Physiology and 4 papers in Pharmacology. Recurrent topics in Andrea Maes's work include Inhalation and Respiratory Drug Delivery (16 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (13 papers) and Asthma and respiratory diseases (13 papers). Andrea Maes is often cited by papers focused on Inhalation and Respiratory Drug Delivery (16 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (13 papers) and Asthma and respiratory diseases (13 papers). Andrea Maes collaborates with scholars based in United States, Poland and Netherlands. Andrea Maes's co-authors include John A. Wagner, Gary Herman, Michael J. Davies, Keith Gottesdiener, Kenneth C. Lasseter, Goutam C. Mistry, Colin Reisner, Shahid Siddiqui, Chad Orevillo and Ubaldo J. Martin and has published in prestigious journals such as CHEST Journal, British Journal of Clinical Pharmacology and European Journal of Pharmaceutical Sciences.

In The Last Decade

Andrea Maes

32 papers receiving 668 citations

Peers

Countries citing papers authored by Andrea Maes

Since Specialization

Citations

This map shows the geographic impact of Andrea Maes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Maes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Maes more than expected).

Fields of papers citing papers by Andrea Maes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrea Maes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Maes. The network helps show where Andrea Maes may publish in the future.

Co-authorship network of co-authors of Andrea Maes

This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Maes. A scholar is included among the top collaborators of Andrea Maes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Maes. Andrea Maes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dose-Ranging and Cumulative Dose Studies of Albuterol Sulfate MDI in Co-Suspension Delivery™ Technology (AS MDI; PT007) in Patients with Asthma: the ASPEN and ANTORA Trials 2021 ·Clinical Drug Investigation ·(unknown), Andrea Maes, (unknown), Michael Gillen, Craig LaForce, Edward Kerwin, Colin Reisner	4
2	Albuterol/budesonide for the treatment of exercise-induced bronchoconstriction in patients with asthma 2021 ·Annals of Allergy Asthma & Immunology ·Craig LaForce, Bradley E. Chipps, Frank C. Albers, Laurence Reilly, Eva Johnsson, (unknown), (unknown), Andrea Maes, Alberto Papi	7
3	<p>Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD</p> 2020 ·International Journal of COPD ·Rongchang Chen, Nanshan Zhong, Haoyan Wang, Li Zhao, Xiaodong Mei, (unknown), (unknown), Pryseley Nkouibert Assam, Andrea Maes, Shahid Siddiqui, Ubaldo J. Martin, Colin Reisner	6
4	Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD 2018 ·International Journal of COPD ·Yasushi Fukushima, Yuji Nakatani, Yumiko Ide, Hisakuni Sekino, Earl St. Rose, Shahid Siddiqui, Andrea Maes, Colin Reisner	6
5	An Open-Label Study Evaluating the Performance of the Dose Indicator in a Metered Dose Inhaler Delivering Glycopyrrolate and Formoterol Fumarate in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease 2018 ·Journal of Aerosol Medicine and Pulmonary Drug Delivery ·(unknown), Gregory Feldman, Faisal Fakih, Peter Mack, Andrea Maes, Shahid Siddiqui, Earl St. Rose, Colin Reisner	3
6	Pharmacokinetics of glycopyrronium/formoterol <br />fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD 2018 ·International Journal of COPD ·Gary T. Ferguson, Roberto Rodríguez-Roisin, Colin Reisner, Andrea Maes, Shahid Siddiqui, Ubaldo J. Martin	13
7	Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects 2018 ·Pulmonary Pharmacology & Therapeutics ·Colin Reisner, J. A. Miller, Paolo B. DePetrillo, Andrea Maes, Shahid Siddiqui, Ubaldo J. Martin	8
8	Randomized study of the effects of Aerochamber Plus® Flow-Vu® on the efficacy, pharmacokinetics and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler in patients with chronic obstructive pulmonary disease 2018 ·Respiratory Medicine ·Faisal Fakih, Selwyn Spangenthal, Barry Sigal, Patrick Darken, Andrea Maes, Shahid Siddiqui, Michael Gillen, Colin Reisner, Ubaldo J. Martin	10
9	Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology 2018 ·Pulmonary Pharmacology & Therapeutics ·Gary T. Ferguson, Colin Reisner, (unknown), Paolo B. DePetrillo, Andrea Maes, Ubaldo J. Martin	6
10	Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent 2018 ·Pulmonary Pharmacology & Therapeutics ·Paul Dorinsky, Paolo B. DePetrillo, Shahid Siddiqui, Andrea Maes, Colin Reisner	5
11	Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology 2017 ·European Journal of Pharmaceutical Sciences ·Glyn Taylor, Simon Warren, Sarvajna Dwivedi, (unknown), (unknown), Chad Orevillo, Andrea Maes, Ubaldo J. Martin, Omar S. Usmani	37
12	Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease 2017 ·Respiratory Medicine ·Nicola A. Hanania, Donald P. Tashkin, Edward Kerwin, James F. Donohue, Michael Denenberg, Denis E. O’Donnell, Dean Quinn, Shahid Siddiqui, Chad Orevillo, Andrea Maes, Colin Reisner	57
13	Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD 2016 ·CHEST Journal ·Fernando J. Martínez, Klaus F. Rabe, Gary T. Ferguson, Leonardo M. Fabbri, Stephen I. Rennard, Gregory Feldman, Sanjay Sethi, Selwyn Spangenthal, Gregory Gottschlich, Roberto Rodríguez-Roisin, Samir Arora, Thomas M. Siler, Shahid Siddiqui, Patrick Darken, Tracy Fischer, Andrea Maes, Michael A. Golden, Chad Orevillo, Colin Reisner	94
14	Human Abuse Potential and Cognitive Effects of Taranabant, a Cannabinoid 1 Receptor Inverse Agonist 2012 ·Journal of Clinical Psychopharmacology ·Kerri A. Schoedel, Carol Addy, Bijan Chakraborty, Kim Rosko, Stephanie Dunbar, Andrea Maes, Nancy Chen, S. Aubrey Stoch, John A. Wagner, (unknown), Edward M. Sellers	11
15	Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects 2011 ·Biopharmaceutics & Drug Disposition ·Rajesh Krishna, Daria Stypinski, (unknown), Amit Garg, Isaias Noel Gendrano, Andrea Maes, (unknown), Yang Liu, (unknown), (unknown), John A. Wagner, S. Aubrey Stoch	11
16	Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma 2011 ·Cancer Chemotherapy and Pharmacology ·David A. Reardon, Timothy F. Cloughesy, Jeremy N. Rich, W.K. Alfred Yung, Lotus Yung, Clifford DiLea, (unknown), Margaret Dugan, William Mietlowski, Andrea Maes, Charles A. Conrad	11
17	Estimating time to steady state using the effective rate of drug accumulation 2009 ·Pharmaceutical Statistics ·Deborah Panebianco, Andrea Maes	2
18	Pharmacokinetics, Safety, and Tolerability of Phentermine in Healthy Participants Receiving Taranabant, a Novel Cannabinoid‐1 Receptor (CB1R) Inverse Agonist 2009 ·The Journal of Clinical Pharmacology ·Carol Addy, Patricia Jumes, (unknown), (unknown), Hankun Li, Andrea Maes, (unknown), Jeffrey Chodakewitz, S. Aubrey Stoch, John A. Wagner	5
19	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid‐1 Receptor Inverse Agonist, for the Treatment of Obesity: Results From a Double‐Blind, Placebo‐Controlled, Single Oral Dose Study in Healthy Volunteers 2008 ·The Journal of Clinical Pharmacology ·Carol Addy, (unknown), Nancy Agrawal, Julie A. Stone, Anup Majumdar, L. Zhong, Hankun Li, Jinyu Yuan, Andrea Maes, Paul Rothenberg, Josée Côté, Kim Rosko, (unknown), Steve Warrington, Malcolm Boyce, Keith Gottesdiener, Aubrey Stoch, John A. Wagner	39
20	Evaluation of Methods for Estimating Time to Steady State with Examples from Phase 1 Studies 2008 ·The AAPS Journal ·(unknown), Deborah Panebianco, Andrea Maes	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact